Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics Study of BGM0504 in Healthy Participants and Participants With Impaired Renal Function
NCT06929156Phase 1Completed
- Sponsor
- BrightGene Bio-Medical Technology
- Start
- May 2025
- Primary completion
- Dec 2025
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of BGM0504 in type 2 diabetes mellitus (T2DM) and obesity (4 arms), sponsored by BrightGene Bio-Medical Technology. Primary endpoints: Area Under the Concentration Versus Time Curve From Time Zero to Tlast at Day 29, Maximum Concentration at Day 29 and 1 more. Started May 2025; status: completed.
02
Drugs
BGM0504
03
Conditions
type 2 diabetes mellitus (T2DM)obesity
Beyond the preview
Go deeper on NCT06929156.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06929156.